Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Treatment According to a Comprehensive Molecular Profiling Can Lead to a Better Outcome in Heavily Pretreated Patients With Metastatic Cancer: Data of a Pooled Analysis.

Seeber A, Chahine G, Nasr F, Dean A, Miranova M, Jameson G, Robert N, Gastl G, Zwierzina H.

Cancer J. 2019 Mar/Apr;25(2):73-79. doi: 10.1097/PPO.0000000000000358.

PMID:
30896526
2.

Innovation in oncology clinical trial design.

Verweij J, Hendriks HR, Zwierzina H; Cancer Drug Development Forum.

Cancer Treat Rev. 2019 Mar;74:15-20. doi: 10.1016/j.ctrv.2019.01.001. Epub 2019 Jan 4. Review.

PMID:
30665053
3.

3D-cultivation of NSCLC cell lines induce gene expression alterations of key cancer-associated pathways and mimic in-vivo conditions.

Gamerith G, Rainer J, Huber JM, Hackl H, Trajanoski Z, Koeck S, Lorenz E, Kern J, Kofler R, Kelm JM, Zwierzina H, Amann A.

Oncotarget. 2017 Nov 6;8(68):112647-112661. doi: 10.18632/oncotarget.22636. eCollection 2017 Dec 22.

4.

Aviscumine, a recombinant ribosomal inhibitor, increases the antitumor activity of natural killer cells.

Gamerith G, Amann A, Schenk B, Auer T, Lentzen H, Mügge DO, Cima KM, Löffler-Ragg J, Hilbe W, Zwierzina H.

Oncol Lett. 2017 Nov;14(5):5563-5568. doi: 10.3892/ol.2017.6861. Epub 2017 Aug 31.

5.

The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3+CD8+ tumor infiltrating lymphocyte subpopulations.

Koeck S, Kern J, Zwierzina M, Gamerith G, Lorenz E, Sopper S, Zwierzina H, Amann A.

Oncoimmunology. 2017 May 8;6(6):e1323617. doi: 10.1080/2162402X.2017.1323617. eCollection 2017.

6.

Development of a 3D angiogenesis model to study tumour - endothelial cell interactions and the effects of anti-angiogenic drugs.

Amann A, Zwierzina M, Koeck S, Gamerith G, Pechriggl E, Huber JM, Lorenz E, Kelm JM, Hilbe W, Zwierzina H, Kern J.

Sci Rep. 2017 Jun 7;7(1):2963. doi: 10.1038/s41598-017-03010-6.

7.

Implementing liquid biopsies into clinical decision making for cancer immunotherapy.

Quandt D, Dieter Zucht H, Amann A, Wulf-Goldenberg A, Borrebaeck C, Cannarile M, Lambrechts D, Oberacher H, Garrett J, Nayak T, Kazinski M, Massie C, Schwarzenbach H, Maio M, Prins R, Wendik B, Hockett R, Enderle D, Noerholm M, Hendriks H, Zwierzina H, Seliger B.

Oncotarget. 2017 Jul 18;8(29):48507-48520. doi: 10.18632/oncotarget.17397. Review.

8.

Treatment of patients with refractory metastatic cancer according to molecular profiling on tumor tissue in the clinical routine: an interim-analysis of the ONCO-T-PROFILE project.

Seeber A, Gastl G, Ensinger C, Spizzo G, Willenbacher W, Kocher F, Leitner C, Willenbacher E, Amann A, Steiner N, Eisterer W, Voss A, Russell K, Zwierzina H.

Genes Cancer. 2016 Sep;7(9-10):301-308. doi: 10.18632/genesandcancer.121.

9.

Evaluation of assays for drug efficacy in a three-dimensional model of the lung.

Huber JM, Amann A, Koeck S, Lorenz E, Kelm JM, Obexer P, Zwierzina H, Gamerith G.

J Cancer Res Clin Oncol. 2016 Sep;142(9):1955-66. doi: 10.1007/s00432-016-2198-0. Epub 2016 Jul 16.

10.

The impact of metformin and salinomycin on transforming growth factor β-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines.

Koeck S, Amann A, Huber JM, Gamerith G, Hilbe W, Zwierzina H.

Oncol Lett. 2016 Apr;11(4):2946-2952. Epub 2016 Mar 9.

11.

Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers.

Koeck S, Zwierzina M, Huber JM, Bitsche M, Lorenz E, Gamerith G, Dudas J, Kelm JM, Zwierzina H, Amann A.

Immunobiology. 2016 May;221(5):604-17. doi: 10.1016/j.imbio.2015.12.010. Epub 2016 Feb 1.

PMID:
26876590
12.

Novel technologies and emerging biomarkers for personalized cancer immunotherapy.

Yuan J, Hegde PS, Clynes R, Foukas PG, Harari A, Kleen TO, Kvistborg P, Maccalli C, Maecker HT, Page DB, Robins H, Song W, Stack EC, Wang E, Whiteside TL, Zhao Y, Zwierzina H, Butterfield LH, Fox BA.

J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016. Review.

13.

Access to innovative oncology medicines in Europe.

Bergmann L, Enzmann H, Thirstrup S, Schweim JK, Widera I, Zwierzina H.

Ann Oncol. 2016 Feb;27(2):353-6. doi: 10.1093/annonc/mdv547. Epub 2015 Nov 16. No abstract available.

14.

Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.

Vassal G, Rousseau R, Blanc P, Moreno L, Bode G, Schwoch S, Schrappe M, Skolnik J, Bergman L, Bradley-Garelik MB, Saha V, Pearson A, Zwierzina H.

Eur J Cancer. 2015 Jan;51(2):218-24. doi: 10.1016/j.ejca.2014.10.029. Epub 2014 Nov 27.

15.

Development of an innovative 3D cell culture system to study tumour--stroma interactions in non-small cell lung cancer cells.

Amann A, Zwierzina M, Gamerith G, Bitsche M, Huber JM, Vogel GF, Blumer M, Koeck S, Pechriggl EJ, Kelm JM, Hilbe W, Zwierzina H.

PLoS One. 2014 Mar 24;9(3):e92511. doi: 10.1371/journal.pone.0092511. eCollection 2014.

16.

Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

Bartsch R, Frings S, Marty M, Awada A, Berghoff AS, Conte P, Dickin S, Enzmann H, Gnant M, Hasmann M, Hendriks HR, Llombart A, Massacesi C, von Minckwitz G, Penault-Llorca F, Scaltriti M, Yarden Y, Zwierzina H, Zielinski CC; Biotherapy Development Association (BDA).

Ann Oncol. 2014 Apr;25(4):773-80. doi: 10.1093/annonc/mdt531. Epub 2013 Dec 18.

PMID:
24351401
17.

Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.

Gamerith G, Auer T, Amann A, Putzer D, Schenk B, Kircher B, Hilbe W, Zwierzina H, Loeffler-Ragg J.

Cancer Biol Ther. 2014 Mar 1;15(3):266-70. doi: 10.4161/cbt.27327. Epub 2013 Dec 18.

18.

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

Bergmann L, Enzmann H, Broich K, Hebborn A, Marsoni S, Goh L, Smyth JF, Zwierzina H.

Ann Oncol. 2014 Feb;25(2):303-6. doi: 10.1093/annonc/mdt488. Epub 2013 Dec 10. No abstract available.

PMID:
24335759
19.

Cancer classification using the Immunoscore: a worldwide task force.

Galon J, Pagès F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Arndt H, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, Pawelec G, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA.

J Transl Med. 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205. Review.

20.

Defining the critical hurdles in cancer immunotherapy.

Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Håkansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Melief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, Pawelec G, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML.

J Transl Med. 2011 Dec 14;9:214. doi: 10.1186/1479-5876-9-214.

21.

Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group.

Baron F, Suciu S, Amadori S, Muus P, Zwierzina H, Denzlinger C, Delforge M, Thyss A, Selleslag D, Indrak K, Ossenkoppele G, de Witte T.

Haematologica. 2012 Apr;97(4):529-33. doi: 10.3324/haematol.2011.044347. Epub 2011 Nov 18.

22.

The preclinical and clinical activity of aviscumine: a potential anticancer drug.

Zwierzina H, Bergmann L, Fiebig H, Aamdal S, Schöffski P, Witthohn K, Lentzen H.

Eur J Cancer. 2011 Jul;47(10):1450-7. doi: 10.1016/j.ejca.2011.02.022. Epub 2011 Apr 12. Review.

PMID:
21482461
23.

Preventive therapy for breast cancer: a consensus statement.

Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, Forbes JF, Glaus A, Howell A, von Minckwitz G, Vogel V, Zwierzina H.

Lancet Oncol. 2011 May;12(5):496-503. doi: 10.1016/S1470-2045(11)70030-4. Review.

PMID:
21441069
24.

Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.

Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Håkansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll H, Siena S, Tabernero J, Van Cutsem E.

Curr Opin Mol Ther. 2010 Dec;12(6):703-11. Review.

PMID:
21154162
25.

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.

Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R.

Crit Rev Oncol Hematol. 2011 May;78(2):150-61. doi: 10.1016/j.critrevonc.2010.05.008. Epub 2010 Jun 26.

PMID:
20580567
26.

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

Bergmann L, Berns B, Dalgleish AG, von Euler M, Hecht TT, Lappin GL, Reed N, Palmeri S, Smyth J, Embacher-Aichorn S, Zwierzina H; Biotherapy Development Association.

Ann Oncol. 2010 Aug;21(8):1573-8. doi: 10.1093/annonc/mdq018. Epub 2010 Feb 4. Review.

PMID:
20133383
27.

Third consensus on medical treatment of metastatic breast cancer.

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; Central European Cooperative Oncology Group (CECOG).

Ann Oncol. 2009 Nov;20(11):1771-85. doi: 10.1093/annonc/mdp261. Epub 2009 Jul 16. Review.

PMID:
19608616
28.

Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.

Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, Skvortsova I, Schmitz KJ, Martin HJ, Krugmann J, Alakus H, Maser E, Menzel J, Hilbe W, Lindner H, Schmid KW, Zwierzina H.

Mol Cancer Ther. 2009 Jul;8(7):1995-2006. doi: 10.1158/1535-7163.MCT-08-0987. Epub 2009 Jun 30.

29.

Improving the efficacy of cancer immunotherapy.

Copier J, Dalgleish AG, Britten CM, Finke LH, Gaudernack G, Gnjatic S, Kallen K, Kiessling R, Schuessler-Lenz M, Singh H, Talmadge J, Zwierzina H, Håkansson L.

Eur J Cancer. 2009 May;45(8):1424-31. doi: 10.1016/j.ejca.2008.12.017. Epub 2009 Jan 21. Review.

PMID:
19167214
30.

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers".

Butterfield LH, Disis ML, Fox BA, Lee PP, Khleif SN, Thurin M, Trinchieri G, Wang E, Wigginton J, Chaussabel D, Coukos G, Dhodapkar M, Håkansson L, Janetzki S, Kleen TO, Kirkwood JM, Maccalli C, Maecker H, Maio M, Malyguine A, Masucci G, Palucka AK, Potter DM, Ribas A, Rivoltini L, Schendel D, Seliger B, Selvan S, Slingluff CL Jr, Stroncek DF, Streicher H, Wu X, Zeskind B, Zhao Y, Zocca MB, Zwierzina H, Marincola FM.

J Transl Med. 2008 Dec 23;6:81. doi: 10.1186/1479-5876-6-81.

31.

Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.

McCabe C, Bergmann L, Bosanquet N, Ellis M, Enzmann H, von Euler M, Jönsson B, Kallen KJ, Newling D, Nüssler V, Paschen B, de Wilde R, Wilking N, Teale C, Zwierzina H; Biotherapy Development Association.

Ann Oncol. 2009 Mar;20(3):403-12. doi: 10.1093/annonc/mdn603. Epub 2008 Oct 14. Review.

PMID:
18854550
32.

EGFR inhibition as a therapy for head and neck squamous cell carcinoma.

Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H.

Expert Opin Investig Drugs. 2008 Oct;17(10):1517-31. doi: 10.1517/13543784.17.10.1517 . Review.

PMID:
18808311
33.

Combining immunotherapy with classical anticancer therapy.

Zwierzina H.

Ann Oncol. 2008 Sep;19 Suppl 7:vii252-5. doi: 10.1093/annonc/mdn482. No abstract available.

PMID:
18790962
34.

Biomarkers in drug development.

Zwierzina H.

Ann Oncol. 2008 Jul;19 Suppl 5:v33-7. doi: 10.1093/annonc/mdn309. No abstract available.

PMID:
18611896
35.

Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).

Bergmann L, Aamdal S, Marreaud S, Lacombe D, Herold M, Yamaguchi T, Wilhelm-Ogunbiyi K, Lentzen H, Zwierzina H; European Organisation for Research and Treatment of Cancer.

Eur J Cancer. 2008 Aug;44(12):1657-62. doi: 10.1016/j.ejca.2008.05.005. Epub 2008 Jul 2.

PMID:
18602257
36.

Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck.

Schwentner I, Witsch-Baumgartner M, Sprinzl GM, Krugmann J, Tzankov A, Jank S, Zwierzina H, Loeffler-Ragg J.

Head Neck. 2008 Aug;30(8):1040-4. doi: 10.1002/hed.20831.

PMID:
18528899
37.

Cetuximab inhibits thymidylate synthase in colorectal cells expressing epidermal growth factor receptor.

Skvortsov S, Sarg B, Lindner H, Lukas P, Hilbe W, Zwierzina H, Skvortsova I.

Proteomics Clin Appl. 2008 Jun;2(6):908-14. doi: 10.1002/prca.200780034.

PMID:
21136888
38.

Antitumor activity of CTFB, a novel anticancer agent, is associated with the down-regulation of nuclear factor-kappaB expression and proteasome activation in head and neck squamous carcinoma cell lines.

Skvortsov S, Skvortsova I, Stasyk T, Schiefermeier N, Neher A, Gunkel AR, Bonn GK, Huber LA, Lukas P, Pleiman CM, Zwierzina H.

Mol Cancer Ther. 2007 Jun;6(6):1898-908.

39.

Identification of endosomal epidermal growth factor receptor signaling targets by functional organelle proteomics.

Stasyk T, Schiefermeier N, Skvortsov S, Zwierzina H, Peränen J, Bonn GK, Huber LA.

Mol Cell Proteomics. 2007 May;6(5):908-22. Epub 2007 Feb 10.

40.

Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes.

Loeffler-Ragg J, Steurer M, Ulmer H, Skvortsov S, Kircher B, Herold M, Zwierzina H, Stauder R.

Leukemia. 2006 Nov;20(11):2064-7. Epub 2006 Sep 7. No abstract available.

PMID:
16990777
41.

Second consensus on medical treatment of metastatic breast cancer.

Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H.

Ann Oncol. 2007 Feb;18(2):215-25. Epub 2006 Jul 10. Review.

PMID:
16831851
42.

Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms.

Skvortsova I, Skvortsov S, Popper BA, Haidenberger A, Saurer M, Gunkel AR, Zwierzina H, Lukas P.

J Radiat Res. 2006 Jun;47(2):183-96.

43.

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.

Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G, Zwierzina H.

Eur J Cancer. 2006 Jan;42(1):109-11. Epub 2005 Dec 1.

PMID:
16324836
44.

[Clinical development of targeted moledular cancer drugs].

Zwierzina H, Borner M.

Onkologie. 2005 Oct;28 Suppl 4:35-9. Epub 2005 Oct 3. German. No abstract available.

PMID:
16205104
45.

Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.

Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H.

Apoptosis. 2005 Oct;10(5):1175-86.

PMID:
16151650
46.

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.

Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group.

Leukemia. 2005 Nov;19(11):1929-33.

PMID:
16151466
47.

Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.

Loeffler-Ragg J, Skvortsov S, Sarg B, Skvortsova I, Witsch-Baumgartner M, Mueller D, Lindner H, Zwierzina H.

Eur J Cancer. 2005 Oct;41(15):2338-46. Epub 2005 Aug 22.

PMID:
16115757
48.

Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells.

Skvortsova I, Popper BA, Skvortsov S, Saurer M, Auer T, Moser R, Kamleitner H, Zwierzina H, Lukas P.

J Radiat Res. 2005 Jun;46(2):241-8.

49.

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer.

Jayson GC, Mulatero C, Ranson M, Zweit J, Jackson A, Broughton L, Wagstaff J, Hakansson L, Groenewegen G, Lawrance J, Tang M, Wauk L, Levitt D, Marreaud S, Lehmann FF, Herold M, Zwierzina H; European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2005 Mar;41(4):555-63. Epub 2005 Jan 22.

PMID:
15737560
50.

Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment.

Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K, Zwierzina H.

Mol Cancer Ther. 2004 Dec;3(12):1551-8.

Supplemental Content

Loading ...
Support Center